BVNRY
Price
$12.37
Change
-$0.01 (-0.08%)
Updated
Aug 15 closing price
Capitalization
2.91B
DMAC
Price
$6.03
Change
+$0.02 (+0.33%)
Updated
Aug 15 closing price
Capitalization
311.68M
81 days until earnings call
Interact to see
Advertisement

BVNRY vs DMAC

Header iconBVNRY vs DMAC Comparison
Open Charts BVNRY vs DMACBanner chart's image
Bavarian Nordic A/S
Price$12.37
Change-$0.01 (-0.08%)
Volume$2.8K
Capitalization2.91B
DiaMedica Therapeutics
Price$6.03
Change+$0.02 (+0.33%)
Volume$125.55K
Capitalization311.68M
BVNRY vs DMAC Comparison Chart in %
Loading...
BVNRY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
DMAC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
BVNRY vs. DMAC commentary
Aug 17, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BVNRY is a Buy and DMAC is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 17, 2025
Stock price -- (BVNRY: $12.37 vs. DMAC: $6.03)
Brand notoriety: BVNRY and DMAC are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BVNRY: 31% vs. DMAC: 33%
Market capitalization -- BVNRY: $2.91B vs. DMAC: $311.68M
BVNRY [@Biotechnology] is valued at $2.91B. DMAC’s [@Biotechnology] market capitalization is $311.68M. The market cap for tickers in the [@Biotechnology] industry ranges from $100.71B to $0. The average market capitalization across the [@Biotechnology] industry is $1.88B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BVNRY’s FA Score shows that 0 FA rating(s) are green whileDMAC’s FA Score has 0 green FA rating(s).

  • BVNRY’s FA Score: 0 green, 5 red.
  • DMAC’s FA Score: 0 green, 5 red.
According to our system of comparison, BVNRY is a better buy in the long-term than DMAC.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BVNRY’s TA Score shows that 3 TA indicator(s) are bullish while DMAC’s TA Score has 6 bullish TA indicator(s).

  • BVNRY’s TA Score: 3 bullish, 5 bearish.
  • DMAC’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, DMAC is a better buy in the short-term than BVNRY.

Price Growth

BVNRY (@Biotechnology) experienced а +0.24% price change this week, while DMAC (@Biotechnology) price change was +29.12% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +9.90%. For the same industry, the average monthly price growth was +26.70%, and the average quarterly price growth was +20.91%.

Reported Earning Dates

DMAC is expected to report earnings on Nov 05, 2025.

Industries' Descriptions

@Biotechnology (+9.90% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
BVNRY($2.91B) has a higher market cap than DMAC($312M). BVNRY YTD gains are higher at: 42.086 vs. DMAC (11.050). BVNRY has higher annual earnings (EBITDA): 2.01B vs. DMAC (-29.04M). BVNRY has more cash in the bank: 1.24B vs. DMAC (36.3M). DMAC has less debt than BVNRY: DMAC (316K) vs BVNRY (117M). BVNRY has higher revenues than DMAC: BVNRY (6.23B) vs DMAC (0).
BVNRYDMACBVNRY / DMAC
Capitalization2.91B312M933%
EBITDA2.01B-29.04M-6,928%
Gain YTD42.08611.050381%
P/E Ratio14.08N/A-
Revenue6.23B0-
Total Cash1.24B36.3M3,405%
Total Debt117M316K37,025%
FUNDAMENTALS RATINGS
BVNRY vs DMAC: Fundamental Ratings
BVNRY
DMAC
OUTLOOK RATING
1..100
2924
VALUATION
overvalued / fair valued / undervalued
1..100
49
Fair valued
70
Overvalued
PROFIT vs RISK RATING
1..100
86100
SMR RATING
1..100
6197
PRICE GROWTH RATING
1..100
3838
P/E GROWTH RATING
1..100
84100
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

BVNRY's Valuation (49) in the null industry is in the same range as DMAC (70) in the Biotechnology industry. This means that BVNRY’s stock grew similarly to DMAC’s over the last 12 months.

BVNRY's Profit vs Risk Rating (86) in the null industry is in the same range as DMAC (100) in the Biotechnology industry. This means that BVNRY’s stock grew similarly to DMAC’s over the last 12 months.

BVNRY's SMR Rating (61) in the null industry is somewhat better than the same rating for DMAC (97) in the Biotechnology industry. This means that BVNRY’s stock grew somewhat faster than DMAC’s over the last 12 months.

BVNRY's Price Growth Rating (38) in the null industry is in the same range as DMAC (38) in the Biotechnology industry. This means that BVNRY’s stock grew similarly to DMAC’s over the last 12 months.

BVNRY's P/E Growth Rating (84) in the null industry is in the same range as DMAC (100) in the Biotechnology industry. This means that BVNRY’s stock grew similarly to DMAC’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BVNRYDMAC
RSI
ODDS (%)
Bearish Trend 2 days ago
63%
Bearish Trend 2 days ago
89%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
69%
Bearish Trend 2 days ago
85%
Momentum
ODDS (%)
N/A
Bullish Trend 2 days ago
85%
MACD
ODDS (%)
Bearish Trend 2 days ago
79%
Bullish Trend 2 days ago
88%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
57%
Bullish Trend 2 days ago
83%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
66%
Bullish Trend 2 days ago
82%
Advances
ODDS (%)
Bullish Trend 9 days ago
70%
Bullish Trend 2 days ago
84%
Declines
ODDS (%)
Bearish Trend 2 days ago
74%
Bearish Trend 6 days ago
81%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
79%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bullish Trend 2 days ago
64%
Bullish Trend 2 days ago
81%
View a ticker or compare two or three
Interact to see
Advertisement
BVNRY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
DMAC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
GBFAX15.730.05
+0.32%
VanEck Emerging Markets A
LZUOX17.93N/A
N/A
Lazard US Equity Focus Open
MARFX23.83N/A
N/A
BlackRock Mid-Cap Value Institutional
FWATX15.08N/A
N/A
Fidelity Advisor Multi-Asset Income A
APGZX121.44N/A
N/A
AB Large Cap Growth Z

DMAC and

Correlation & Price change

A.I.dvisor indicates that over the last year, DMAC has been loosely correlated with WHWK. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if DMAC jumps, then WHWK could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DMAC
1D Price
Change %
DMAC100%
+0.33%
WHWK - DMAC
47%
Loosely correlated
-1.23%
ARCT - DMAC
36%
Loosely correlated
+1.30%
HUMA - DMAC
35%
Loosely correlated
N/A
ELDN - DMAC
30%
Poorly correlated
+1.15%
XOMA - DMAC
30%
Poorly correlated
-0.70%
More